Cargando…

Improving recognition of Duchenne muscular dystrophy: a retrospective case note review

BACKGROUND: Over the last 30 years, there has been little improvement in the age of diagnosis of Duchenne muscular dystrophy (DMD) (mean age of 4.5–4.11 years). AIM: To review the diagnostic process for DMD in boys without a family history in order to identify where delays occur and suggest areas fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ruiten, Henriette J A, Straub, Volker, Bushby, Kate, Guglieri, Michela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251173/ https://www.ncbi.nlm.nih.gov/pubmed/25187493 http://dx.doi.org/10.1136/archdischild-2014-306366

Ejemplares similares

Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)

Compliance to Care Guidelines for Duchenne Muscular Dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2015)

The burden of Duchenne muscular dystrophy: An international, cross-sectional study
por: Landfeldt, Erik, et al.
Publicado: (2014)

Health‐related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross‐sectional study
por: Landfeldt, Erik, et al.
Publicado: (2015)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead
por: Heslop, Emma, et al.
Publicado: (2021)

An update on Becker muscular dystrophy
por: Straub, Volker, et al.
Publicado: (2023)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
por: Landfeldt, Erik, et al.
Publicado: (2016)

MON-LB050 Preliminary Results from the "Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy (DMD) (NCT 02571205)"
por: Wood, Claire, et al.
Publicado: (2019)

Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?
por: Wood, Claire L, et al.
Publicado: (2023)

The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy
por: Wood, CL, et al.
Publicado: (2021)

Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy
por: Burch, Peter M., et al.
Publicado: (2015)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis
por: Broomfield, Jonathan, et al.
Publicado: (2021)

Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy
por: Wood, C. L., et al.
Publicado: (2019)

Adult care for Duchenne muscular dystrophy in the UK
por: Rodger, Sunil, et al.
Publicado: (2014)

Neurocognitive Profiles in Duchenne Muscular Dystrophy and Gene Mutation Site
por: D’Angelo, Maria Grazia, et al.
Publicado: (2011)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Measurement of salivary testosterone in adolescents and young men with Duchenne muscular dystrophy
por: Sahun, Yolanda Alins, et al.
Publicado: (2021)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
por: Cirak, Sebahattin, et al.
Publicado: (2011)

Decoding the transcriptome of Duchenne muscular dystrophy to the single nuclei level reveals clinical-genetic correlations
por: Suárez-Calvet, Xavier, et al.
Publicado: (2023)

Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients
por: PASSAMANO, LUIGIA, et al.
Publicado: (2012)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2019)

Development of a New Quality of Life Measure for Duchenne Muscular Dystrophy Using Mixed Methods: The DMD-QoL
por: Powell, Philip A., et al.
Publicado: (2021)

Duchenne muscular dystrophy: Case report and review
por: Sinha, Rupam, et al.
Publicado: (2017)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
por: Kinali, Maria, et al.
Publicado: (2009)

Improving clinical trial design for Duchenne muscular dystrophy
por: Merlini, Luciano, et al.
Publicado: (2015)

Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy
por: Barthel, Benjamin L., et al.
Publicado: (2021)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t560n5bfa30be3hchh8e55dg5n